Andrew Naylor

Part of Piper Sandler Cos., Piper Sandler Ltd. is a brokerage services provider. The company is based in London, UK. The British company was founded in 1999. Neil Robert Mackison has been the CEO of the company since 2006.

DuPont Pharmaceuticals Co. researches and develops pharmaceuticals and imaging products to treat diseases. It focuses on pharmaceuticals to treat unmet medical needs in the fight against HIV, cardiovascular disease, central nervous system disorders, cancer and arthritis-related disorders. The company is located in Wilmington, DE.

The University of Melbourne, founded in 1853, is a world-renowned institution located in Parkville, Australia. The university is a leader in education, teaching, and research, offering a wide range of coursework and research programs.

Monash University operates as a public research university. It specializes in higher education, global engagement, postgraduate courses, undergraduate study, and PhD research. The company was founded on March 1961 and is headquartered in Clayton, Australia.

Oxford Drug Design Ltd. develops application of new technologies to drive computer-aided drug discovery. It specializes in drug discovery, molecular modeling, lead identification and optimisation, formulation modeling and preclinical studies. The company was founded by W. Graham Richards in 2001 and is headquartered in Oxford, the United Kingdom.

Uniseed Management Pty Ltd. (Uniseed) is an independent Australian venture capital firm which was founded in 2000. The firm headquartered in Australia.

The BioIndustry Association is a UK-based organization that represents the life sciences and biotech industry. The British company's mission is to facilitate and connect the ecosystem to help businesses start, grow, and deliver world-changing innovation. The non-profit company was founded by Cormac G. Kilty and Simon Geoffrey Best, and Steve Bates has been the CEO of the company since 2012.

Arecor Ltd. provides stabilization technology solutions. The firm's products include ultra-rapid acting prandial insulin, stable aqueous glucagon, ultra concentrated insulin and additional programs. The company was founded by Paul James Davis in 2007 and is headquartered in Cambridge, the United Kingdom.

Aitua Ltd. engages in the commercialization of intellectual properties of companies in the field of life sciences. It provides support to new bio-ventures by investing in the initial stage. The company was founded in June 2006 and is headquartered in Cambridge, the United Kingdom.

PBL-Ventures is the business start-up and mentoring arm of Plant Bioscience Ltd founded in 1994. The firm is headquartered in the UK.

Hatchtech Pty Ltd. operates as pharmaceutical product company. It offers Xeglyze lotion that is head lice treatment. The company was founded by Vernon Morrison Bowles in 2001 and is headquartered in in Melbourne, Australia.

Isogenica Ltd. provides research and development services in the fields of new peptide, antibody and other polypeptide drug candidates. It offers llamdA System, Xab System and 4D Fab System. The company was founded by Kevin Fitzgerald in 2000 and is headquartered in Little Chesterford, the United Kingdom.

Sage Healthcare Ltd. provides management consulting services to the healthcare industry. The firm's services include strategic analysis and development; mergers and acquisitions; business development, support, and planning; corporate partnering; licensing and venturing; technology and compound brokerage; valuations and value-enhancement planning; forecasting; risk assessment and due diligence; and commercial and technical assessment. The company was founded in 1995 and is headquartered in Great Shelford, GB.

Locate Bio Ltd. operates as a regenerative medicine development company. The firm focuses on clinical problems in which regeneration of human tissue will displace biomaterial or drug therapies. Its products are orthopaedic matrices with unique properties for hard to heal clinical applications. The company was founded by Robin Quirk and is headquartered in Nottingham, the United Kingdom.

Fibrotech Therapeutics Pty Ltd develops novel drug candidates for the treatment of the fibrosis prevalent in such chronic conditions as kidney disease, chronic heart failure, pulmonary fibrosis, and arthritis. The company was founded by Richard Ernest Gilbert, Darren James Kelly, Spencer J Williams, Steven C Zammit, David Stapleton, Henry Krum and Yuan Zhang in 2006 and is headquartered in Melbourne, Australia.

CFA Society of the UK is an association of investment professionals based in the UK. The British company was founded in an unspecified year.

Otifex Therapeutics Pty Ltd. develops treatment for ear diseases. The company was founded by Burkhard Franz and Colin Anderson in 2009 and is headquartered in Melbourne, Australia.

Nexgen Plants Pty Ltd. develops anti-viral technology solutions that enables virus resistant plant varieties to be developed for major food, fibre, energy and ornamental crops. The company was founded in 2013 and is headquartered in St. Lucia, Australia.

PhoreMost Ltd. operates as a drug discovery company. It engages in identifying new druggable targets for cancer and other unmet diseases. PhoreMost uses SiteSeeker technology, a live-cell phenotypic assay system that can identify unexpected, or cryptic druggable sites in specific disease driving targets and pathways that can?t be readily seen using conventional non-cell based analytical methods. The company was founded by Christopher John Torrance and Ashok Venkitaraman on April 1, 2014 and is headquartered in Cambridge, the United Kingdom.

OccuRx Pty Ltd provides biopharmaceutical services. It engages in the development of therapeutic strategies for the treatment of ophthalmic disorders associated with retinal fibrosis and inflammation. The company was founded by Darren J. Kelly in 2014 and is headquartered in Melbourne, Australia.

O2h Ltd (O2h) is a venture capital firm. The firm is founded by Sunil and Prashant Shah. It is headquartered in United Kingdom.

Opal Oncology Ltd. operates as a pharmaceutical company. It develops drugs for cancer. The company was founded in 2012 and is headquartered in Cambridge, the United Kingdom.

Small Pharma Ltd. operates as a pharmaceutical company that develops a rapid-acting antidepressant to treat patients with depression. The company was founded by Peter Rands in 2015 and is headquartered in London, the United Kingdom.

NeoPhore Ltd. engages in discovery and development of small molecules inhibitors to treat cancer. The company is headquartered in Kings Cross, London, the United Kingdom.

Five Alarm Bio Ltd. is a drug discovery firm that develops compounds that boost bodies’ ability to defend self against the damage of aging. It focuses on novel approaches to anti-aging, with broad potential therapeutic application. The company was founded by William Arthur Bains, Sunil Rajen Shah, and Ann Baker in 2016 and is headquartered in Cambridge, the United Kingdom.

Ena Respiratory Pty Ltd. operates as a biotechnology company. It develops novel, synthetic innate immunomodulators for the prevention of respiratory viral and bacterial infections. The company is headquartered in Melbourne, Australia.

Stingray Bio Ltd. is a British biotechnology research company founded in 2020. The company is based in Brighton, UK. The company provides research services in the field of biotechnology.

Enhanc3D Genomics is a private functional genomics company based in Cambridge, UK. Enhanc3D Genomics is developing a technology to unlock the full potential of the three-dimensional organization of the human genome. The British company's focus is on the non-coding regions of the genome, aiming to identify disease-associated genetic interactions and revolutionize target and biomarker discovery. The company's unique approach has the potential to make precision medicine an everyday reality for patients. Enhanc3D Genomics Ltd. was founded by Mikhail Spivakov, Peter Fraser, and Stefan Schönfelder. The CEO is Hazel Jones.

Alevin Therapeutics Ltd. is a British company that focuses on developing safe and effective medicines for patients with life-threatening diseases through targeted integrin therapies. The company is based in Cambridge, UK and was founded in 2022 by Chris Moody, Thomas McInally, Alison John. The company's preclinical pipeline features small molecules that target integrin receptors.

Horizon Discovery Ltd. develops and supplying patient-relevant drug discovery and diagnostic research tools. The frm also supplies genetically-defined cell lines, reporter gene assay kits, genomic reference standards and contract research services to organizations engaged in bio-pharmaceutical process optimization, drug discovery & development, and clinical diagnostic development. The company was founded by Christopher John Torrance and Alberto Bardelli on February 14, 2005 and is headquartered in Cambridge, the United Kingdom.